Mission
Advancing the treatment of gastrointestinal diseases using defined bacterial consortia
We rationally design medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies.
“We believe that in the near future, physicians will have a new option to treat their patients, consisting of oral therapies made from standardized compositions of live bacteria. At Vedanta, we are leading the charge to create this new type of medicine.”
Bernat Olle, Chief Executive Officer
Founded and led by leaders in the fields of immunology and microbiome
We have assembled a team with deep drug development expertise in gastroenterology, infectious diseases, and immunology, as well as leading technical expertise in microbiome research and manufacture of live organisms.
Our scientific founders have pioneered our modern understanding of how the immune system senses microbes, and contributed seminal discoveries to the microbiome field, including the identification of immune-regulating bacteria that live in association with humans and characterization of their mechanisms of action.
Our goal is to leverage our proprietary product engine to develop oral therapies comprised of defined bacterial consortia to treat a wide range of debilitating diseases for patients.
Our Team
We have assembled a team with deep drug development expertise in gastroenterology, infectious diseases, and immunology, as well as leading technical expertise in microbiome research and manufacture of live organisms.
Defined Bacterial Consortia
We are developing oral therapies using defined bacterial consortia to treat a wide range of debilitating diseases with an initial focus on gastrointestinal (GI) diseases.